AIM ImmunoTech Inc. (AIM)
AMEX: AIM
· Real-Time Price · USD
2.69
-0.19 (-6.60%)
At close: Sep 26, 2025, 3:59 PM
2.68
-0.37%
After-hours: Sep 26, 2025, 07:59 PM EDT
AIM ImmunoTech Revenue Breakdown
| Period Ending | Dec 31, 2022 | Jun 30, 2022 |
|---|---|---|
| Clinical Treatment Programs - US Revenue | 111K | 30K |
| Clinical Treatment Programs - US Revenue Growth | +270.00% | n/a |
Revenue by Geography
| Period Ending | Jun 30, 2021 |
|---|---|
| United States Revenue | 23K |
| United States Revenue Growth | n/a |
Operating Expense Breakdown
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 1.49M | 2.54M | 4.29M | 3.08M | 2.59M | 3.76M | 10.8M | 5.44M | 2.55M | 2.29M | 3.5M | 5.17M | 2.18M | 2.07M | 2.62M | 1.8M | 2.15M | 2.11M | 2.58M | 2.08M | 1.72M | 2.27M | 1.48M | 1.85M | 1.94M | 1.77M | 1.63M | 1.27M | 1.73M | 1.56M | 1.73M | 1.56M | 1.62M | 1.66M | 1.96M | 1.63M | 1.64M | 2.45M | 1.55M | 1.69M | 2M | 1.91M |
| Selling, General, and Administrative Revenue Growth | -41.57% | -40.63% | +39.23% | +18.83% | -31.04% | -65.21% | +98.55% | +113.29% | +11.26% | -34.61% | -32.21% | +137.05% | +5.26% | -20.83% | +45.47% | -16.13% | +1.56% | -18.27% | +23.93% | +21.43% | -24.29% | +52.83% | -19.61% | -4.94% | +9.90% | +8.27% | +28.20% | -26.54% | +10.88% | -9.81% | +11.38% | -3.89% | -2.70% | -15.10% | +19.95% | -0.31% | -33.05% | +58.24% | -8.19% | -15.83% | +4.65% | n/a |
| Research and Development Revenue | 1.17M | 1.08M | 1.66M | 1.44M | 1.15M | 1.95M | 3.19M | 2.73M | 2.95M | 2.05M | 2.11M | 1.37M | 2.48M | 1.04M | 2.92M | 2.01M | 1.32M | 1.42M | 2.27M | 1.1M | 1.46M | 898K | 1.44M | 1.19M | 1.1M | 928K | 987K | 1.59M | 1.34M | 855K | 814K | 787K | 1.11M | 1.39M | 1.86M | 1.34M | 900K | 1M | 957K | 1.97M | 2.44M | 2.67M |
| Research and Development Revenue Growth | +8.70% | -35.10% | +15.80% | +25.50% | -41.31% | -38.76% | +16.53% | -7.42% | +43.91% | -2.61% | +53.57% | -44.57% | +138.90% | -64.56% | +45.71% | +52.32% | -7.51% | -37.41% | +106.44% | -24.68% | +62.92% | -37.51% | +20.76% | +8.58% | +18.10% | -5.98% | -38.12% | +18.94% | +56.84% | +5.04% | +3.43% | -28.84% | -20.49% | -25.34% | +38.82% | +49.11% | -10.18% | +4.70% | -51.37% | -19.31% | -8.79% | n/a |